Search results | pancreatic cancer

Reports

Pancreatic Cancer Partnering

The Pancreatic Cancer Partnering provides understanding and access to the pancreatic cancer partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

Celgene

Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey

Merck hunts for smaller drug developers for acquisition

German healthcare group Merck KGaA is looking for acquisitions and collaborations with start-ups to grow its drugs business in the United States, a senior Merck official said.

Celgene: Company Profile

Celgene, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

M&A: Looking to be acquired in 2013?

M&A: Would you rather be smart or lucky?

Top partnering deals so far in 2012

The first six months of 2012 have been busy for life science dealmakers, with significant partnerships across numerous therapy areas

Current Agreements Deal Analysis Update: March 2012

Welcome to the March 2012 edition of Current Agreements Deal Analysis Update

Dealmakers weekly review – February 6 2012 – Merck KgaA, Threshold, Bill and Melinda Gates Foundation, AstraZenenca, Actavis

The week was relatively quiet until the end of week announcement by Merck KGaA of a $550 million partnership with Threshold for the co-development and commercialization of TH-302

Amgen may join Gilead as biotech seeks acquisition to fuel growth

Written by Meg Tirrel, Ryan Flinn and Jeffrey McCracken for Bloomberg. Amgen and Celgene may dive into deal-making this year as the biggest biotechnology companies seek to return to the industry’s high-growth roots.

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals

Events

Sorry, your search returned no results.


Deals

Baxter and Merrimack ink a pharma licensing deal for developing cancer drug

Baxter International had entered into an exclusive pharma licensing and collaboration agreement with Merrimack Pharmaceuticals to develop and commercialize lead cancer drug MM-398.

BMS and Celgene become pharma partners for evaluating cancer drugs

Bristol-Myers Squibb and Celgene become a pharma partners for evaluating the efficacy of combination treatment using  OPDIVO and ABRAXANE.

Big pharma, Astellas joins hands with UK cancer non-profits

Cancer Research UK and Cancer Research Technology are to join forces with big pharma, Astellas Pharma to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

OncoMed pharma partners with Celgene in anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals and Celgene, big biotech company, pharma partners to jointly develop and commercialize up to six anti-cancer stem cell product candidates from OncoMed’s biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4)

AstraZeneca big pharma partners with University of Cambridge and Cancer Research UK

AstraZeneca is pursuing three research projects with pharma partners the University of Cambridge and Cancer Research UK for oncology treatments.

Aduro Biotech gains $51.4 million series D financing

Aduro Biotech announced the closing of a $51.4 million Series D preferred stock financing

BMS and Five Prime partner on Opdivo – FPA008 combination

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008

Pfizer and Kyowa Hakko Kirin start a pharma alliance for immuno-oncology study

Pfizer and Kyowa Hakko Kirin have entered into an pharma alliance agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab.

MacroGenics and Takeda sign a pharma licensing deal for $400 million

MacroGenics and Takeda Pharmaceutical announced inking a pharma licensing deal to develop and commercialize four potential product candidates.

MetaSysX signs a pharma deal with Bayer

MetaSysX announce the closure of a pharma deal with Bayer CropScience for the coming three years to apply its metabolomics technologies for improving agricultural productivity.